Breeding success of the Great Bustard Otis tarda in Zamora Province, Spain, in 1984

Great Bustards are still fairly abundant (5-2 nests/1000 ha) in Zamora. Overall fecundity was high (92% of adult females attempt to nest; 2–47 eggs/clutch; 89% egg fertility), but pre- and post-hatching mortality were also high (50% of eggs laid; 57% of nestlings hatched), due mainly to agricultural machinery but also to natural predators. Calculated annual yields per 100 adult females were: 227 eggs, 102 hatchlings, 44 fledglings. Production of 44 fledglings/y could sustain a stable adult population (mortality approx. 8%/y) if mortality of immatures is not more than 18–22%/y.     

The astragalus of Paleogene artiodactyls: comparative morphology, variability and prediction of body mass

Martinez, J.-N. & Sudre, 1. 1995 11 30 The astragalus of Paleogene artiodactyls: comparative morphology, variability and prediction of body mass. Lethaia , Vol. 28, pp. 197–209. Oslo. ISSN 0024–1164.
The morphology of the astragalus is analysed in nineteen Paleogene artiodactyls (suborders Palaeodonta, Suina, Ancodonta and Ruminantia). This morphology is related to the functional adaptations of the appendicular skeleton, but some diagnostic characters can be seen at the family level. For the populations examined, the proportions of this bone show a low intraspecific variability, which does not allow detection of any dimorphism. An allometric relationship between the dimensions of the astragalus and the body mass has been established for extant species, allowing estimates for the fossil species. In most cases, the interval between the two extreme estimations using the astragalus includes the estimated body mass using M/1 area. The limits of this method are discussed, and it is suggested that the dimensions of the astragalus give a better estimation of the body mass than the dental area. □ Artiodactyls, astragalus, comparative morphology, body mass, allometry, Paleogene .     

Production via good manufacturing practice of exofucosylated human mesenchymal stromal cells for clinical applications

Background

The regenerative and immunomodulatory properties of human mesenchymal stromal cells (hMSCs) have raised great hope for their use in cell therapy. However, when intravenously infused, hMSCs fail to reach sites of tissue injury. Fucose addition in α(1,3)-linkage to terminal sialyllactosamines on CD44 creates the molecule known as hematopoietic cell E-/L-selectin ligand (HCELL), programming hMSC binding to E-selectin that is expressed on microvascular endothelial cells of bone marrow (BM), skin and at all sites of inflammation. Here we describe how this modification on BM-derived hMSCs (BM-hMSCs) can be adapted to good manufacturing practice (GMP) standards.